CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure
I'm PortAI, I can summarize articles.
CalciMedica Inc. is currently enrolling patients in its Phase 2 KOURAGE trial for Auxora™ targeting Stage 2 or 3 acute kidney injury with respiratory failure, aiming for 150 participants and data release in early 2026. The company is also in discussions with the FDA for a pivotal trial in acute pancreatitis, with final design expected in the same timeframe. Preclinical results presented in November 2025 indicated improved kidney function in a rat model. Additionally, CalciMedica has partnered with Telperian to incorporate AI insights into the trial design.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments